Spotlight on the new ACC/AHA lipid and JNC8 hypertension guidelines, EGFR inhibitors vs chemotherapy for NSCLC, and more. | Learning | The JAMA Network
[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Sign in or Create an Account to track your personal CME/MOC activities
0 Credit Audio 9 min 33 sec JAMA April 8, 2014

Spotlight on the new ACC/AHA lipid and JNC8 hypertension guidelines, EGFR inhibitors vs chemotherapy for NSCLC, and more.

×